1. Home
  2. EVO vs MTX Comparison

EVO vs MTX Comparison

Compare EVO & MTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVO
  • MTX
  • Stock Information
  • Founded
  • EVO 1993
  • MTX 1968
  • Country
  • EVO Germany
  • MTX United States
  • Employees
  • EVO N/A
  • MTX N/A
  • Industry
  • EVO Biotechnology: Pharmaceutical Preparations
  • MTX Major Chemicals
  • Sector
  • EVO Health Care
  • MTX Industrials
  • Exchange
  • EVO Nasdaq
  • MTX Nasdaq
  • Market Cap
  • EVO 1.5B
  • MTX 1.7B
  • IPO Year
  • EVO 2021
  • MTX 1992
  • Fundamental
  • Price
  • EVO $4.34
  • MTX $59.03
  • Analyst Decision
  • EVO Buy
  • MTX Strong Buy
  • Analyst Count
  • EVO 2
  • MTX 2
  • Target Price
  • EVO $5.90
  • MTX $80.00
  • AVG Volume (30 Days)
  • EVO 120.0K
  • MTX 248.1K
  • Earning Date
  • EVO 08-13-2025
  • MTX 07-24-2025
  • Dividend Yield
  • EVO N/A
  • MTX 0.76%
  • EPS Growth
  • EVO N/A
  • MTX N/A
  • EPS
  • EVO N/A
  • MTX N/A
  • Revenue
  • EVO $851,944,444.00
  • MTX $2,075,800,000.00
  • Revenue This Year
  • EVO $10.08
  • MTX N/A
  • Revenue Next Year
  • EVO $10.99
  • MTX $4.69
  • P/E Ratio
  • EVO N/A
  • MTX N/A
  • Revenue Growth
  • EVO 1.50
  • MTX N/A
  • 52 Week Low
  • EVO $2.84
  • MTX $49.54
  • 52 Week High
  • EVO $5.64
  • MTX $90.30
  • Technical
  • Relative Strength Index (RSI)
  • EVO 57.99
  • MTX 60.53
  • Support Level
  • EVO $4.15
  • MTX $54.76
  • Resistance Level
  • EVO $4.33
  • MTX $56.19
  • Average True Range (ATR)
  • EVO 0.11
  • MTX 1.44
  • MACD
  • EVO 0.02
  • MTX 0.39
  • Stochastic Oscillator
  • EVO 85.92
  • MTX 99.33

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About MTX Minerals Technologies Inc.

Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of our customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve our customers' manufacturing processes and projects. The majority of revenue comes from the United States.

Share on Social Networks: